• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Wilson 病患者肝脏的脂肪肝和抗氧化酶活性以及过氧化物酶体增殖物激活受体 γ 和 α 的表达。

Fatty liver and anti-oxidant enzyme activities along with peroxisome proliferator-activated receptors γ and α expressions in the liver of Wilson's disease.

机构信息

Department of Pediatrics, Takarazuka City Hospital, 4-5-1 Kohama-cho, Takarazuka 665-0827, Japan.

出版信息

Mol Genet Metab. 2012 Nov;107(3):542-7. doi: 10.1016/j.ymgme.2012.08.004. Epub 2012 Aug 11.

DOI:10.1016/j.ymgme.2012.08.004
PMID:22940187
Abstract

BACKGROUND

The mechanisms of liver damage and steatosis in Wilson's disease (WD) presenting accumulation of copper generating oxidants remain unclear. Recent studies have shown that peroxisome proliferator-activated receptors (PPARs), in particular PPARs α and γ, regulate fat content of the liver together with the anti-oxidant and anti-inflammation systems. However, such PPARs have never been studied in WD.

METHODS

We examined PPARs along with the liver damage and steatosis of WD using liver specimens from affected patients exhibiting mild liver damage (group I, n = 5), moderate or greater liver damage (group II, n = 10) and fulminant hepatic failure (group III, n = 5), and from asymptomatic carriers (group H, n = 4).

RESULTS

PPAR α expression was increased over the control levels in groups H and I but was decreased in groups II and III in parallel with the progression of liver damage (group H = I>II>III). PPAR γ expression was inversely increased (group H<I<II<III). Mn-dependent superoxide dismutase (Mn-SOD), CuZn-SOD, and catalase activities were decreased in the affected three groups, and were increased in group H. Among group II exhibiting substantial inter-individual variances in parameters, the severity of steatosis showed a significant positive correlation with PPAR γ expression (p<0.001) but not PPAR α expression. CuZn-SOD activity was positively correlated with PPARα expression (p<0.05) but not PPAR γ expression.

CONCLUSION

These results suggest that changes of PPARs γ and α are associated with the steatosis and the impairment of anti-oxidant system in the liver of WD.

摘要

背景

Wilson 病(WD)患者体内铜的蓄积会导致肝损伤和脂肪变性,但铜生成氧化剂导致肝损伤和脂肪变性的确切机制仍不清楚。最近的研究表明,过氧化物酶体增殖物激活受体(PPARs),特别是 PPARα和 PPARγ,与抗氧化和抗炎系统一起调节肝脏的脂肪含量。然而,这些 PPARs 在 WD 中从未被研究过。

方法

我们使用来自有轻度肝损伤(I 组,n=5)、中重度肝损伤或肝衰竭(II 组,n=10)和暴发性肝衰竭(III 组,n=5)的 WD 患者的肝组织以及无症状携带者(H 组,n=4)的肝组织,检查了 PPARs 与 WD 患者的肝损伤和脂肪变性的关系。

结果

PPARα的表达在 H 组和 I 组中均高于对照组,但随着肝损伤的进展(H 组>I 组>II 组>III 组),在 II 组和 III 组中则降低。PPARγ的表达呈相反的增加趋势(H 组<I 组<II 组<III 组)。Mn 依赖性超氧化物歧化酶(Mn-SOD)、CuZn-SOD 和过氧化氢酶活性在受影响的三组中均降低,而在 H 组中则升高。在表现出明显个体间差异的 II 组中,脂肪变性的严重程度与 PPARγ的表达呈显著正相关(p<0.001),但与 PPARα的表达无关。CuZn-SOD 活性与 PPARα的表达呈正相关(p<0.05),但与 PPARγ的表达无关。

结论

这些结果表明,PPARγ和 PPARα的变化与 WD 患者肝脏的脂肪变性和抗氧化系统的损伤有关。

相似文献

1
Fatty liver and anti-oxidant enzyme activities along with peroxisome proliferator-activated receptors γ and α expressions in the liver of Wilson's disease.Wilson 病患者肝脏的脂肪肝和抗氧化酶活性以及过氧化物酶体增殖物激活受体 γ 和 α 的表达。
Mol Genet Metab. 2012 Nov;107(3):542-7. doi: 10.1016/j.ymgme.2012.08.004. Epub 2012 Aug 11.
2
Children's toxicology from bench to bed--Liver Injury (3): Oxidative stress and anti-oxidant systems in liver of patients with Wilson disease.儿童毒理学:从实验台到临床——肝损伤(3):威尔逊病患者肝脏中的氧化应激与抗氧化系统
J Toxicol Sci. 2009;34 Suppl 2:SP229-36. doi: 10.2131/jts.34.sp229.
3
Peroxisome proliferator-activated receptor-alpha and -gamma mRNA levels are reduced in chronic hepatitis C with steatosis and genotype 3 infection.在伴有脂肪变性的慢性丙型肝炎及3型基因型感染中,过氧化物酶体增殖物激活受体α和γ的信使核糖核酸水平降低。
Aliment Pharmacol Ther. 2006 Jan 1;23(1):107-14. doi: 10.1111/j.1365-2036.2006.02729.x.
4
Relationship between oxidative stress and antioxidant systems in the liver of patients with Wilson disease: hepatic manifestation in Wilson disease as a consequence of augmented oxidative stress.肝豆状核变性患者肝脏中氧化应激与抗氧化系统的关系:肝豆状核变性的肝脏表现是氧化应激增强的结果。
Pediatr Res. 2006 Oct;60(4):472-7. doi: 10.1203/01.pdr.0000238341.12229.d3. Epub 2006 Aug 28.
5
Direct effects of iodothyronines on excess fat storage in rat hepatocytes.甲状腺激素对大鼠肝细胞内多余脂肪储存的直接影响。
J Hepatol. 2011 Jun;54(6):1230-6. doi: 10.1016/j.jhep.2010.09.027. Epub 2010 Nov 3.
6
Long-term outcomes for 32 cases of Wilson's disease after living-donor liver transplantation.32例Wilson病患者活体肝移植后的长期预后
Transplantation. 2009 Jan 27;87(2):261-7. doi: 10.1097/TP.0b013e3181919984.
7
The relationship between copper and steatosis in Wilson's disease.Wilson 病中铜与脂肪变性的关系。
Clin Res Hepatol Gastroenterol. 2013 Feb;37(1):36-40. doi: 10.1016/j.clinre.2012.03.038. Epub 2012 May 7.
8
Transgenic expression of mutant peroxisome proliferator-activated receptor gamma in liver precipitates fasting-induced steatosis but protects against high-fat diet-induced steatosis in mice.肝脏中突变型过氧化物酶体增殖物激活受体γ的转基因表达会引发禁食诱导的脂肪变性,但可保护小鼠免受高脂饮食诱导的脂肪变性。
Metabolism. 2005 Nov;54(11):1490-8. doi: 10.1016/j.metabol.2005.05.015.
9
Peroxisome proliferator-activated receptors alpha and gamma2 polymorphisms in nonalcoholic fatty liver disease: a study in Brazilian patients.过氧化物酶体增殖物激活受体α和γ2 多态性与非酒精性脂肪性肝病:巴西患者的研究。
Gene. 2013 Oct 25;529(2):326-31. doi: 10.1016/j.gene.2013.06.091. Epub 2013 Jul 24.
10
Pioglitazone ameliorates nonalcoholic steatohepatitis by down-regulating hepatic nuclear factor-kappa B and cyclooxygenases-2 expression in rats.吡格列酮通过下调核因子-κB 和环氧化酶-2 在大鼠肝脏中的表达改善非酒精性脂肪性肝炎。
Chin Med J (Engl). 2012 Jul;125(13):2316-21.

引用本文的文献

1
Development and validation of a nomogram model for prediction of dyslipidemia in children with Wilson disease: a retrospective analysis.肝豆状核变性患儿血脂异常预测列线图模型的建立与验证:一项回顾性分析
Front Endocrinol (Lausanne). 2025 Aug 21;16:1642083. doi: 10.3389/fendo.2025.1642083. eCollection 2025.
2
Copper and hepatic lipid dysregulation: Mechanisms and implications.铜与肝脏脂质代谢失调:机制及影响
World J Hepatol. 2025 Aug 27;17(8):107803. doi: 10.4254/wjh.v17.i8.107803.
3
Therapeutic implications of impaired nuclear receptor function and dysregulated metabolism in Wilson's disease.
Wilson 病中核受体功能障碍和代谢失调的治疗意义。
Pharmacol Ther. 2023 Nov;251:108529. doi: 10.1016/j.pharmthera.2023.108529. Epub 2023 Sep 22.
4
Oxysterol misbalance critically contributes to Wilson disease pathogenesis.氧化甾醇失衡在威尔逊病发病机制中起关键作用。
Sci Adv. 2022 Oct 21;8(42):eadc9022. doi: 10.1126/sciadv.adc9022. Epub 2022 Oct 19.
5
Suppression of Hepatic PPARα in Primary Biliary Cholangitis Is Modulated by miR-155.原发性胆汁性胆管炎中 PPARα 的抑制受 miR-155 调控。
Cells. 2022 Sep 15;11(18):2880. doi: 10.3390/cells11182880.
6
Wilson Disease: Update on Pathophysiology and Treatment.威尔逊病:病理生理学与治疗的最新进展
Front Cell Dev Biol. 2022 May 2;10:871877. doi: 10.3389/fcell.2022.871877. eCollection 2022.
7
Antioxidant Capacity Is Decreased in Wilson's Disease and Correlates to Liver Function.抗氧化能力在威尔逊病中降低,并与肝功能相关。
Biol Trace Elem Res. 2023 Apr;201(4):1582-1587. doi: 10.1007/s12011-022-03277-5. Epub 2022 May 7.
8
NRF2 and PPAR-γ Pathways in Oligodendrocyte Progenitors: Focus on ROS Protection, Mitochondrial Biogenesis and Promotion of Cell Differentiation.NRF2 和 PPAR-γ 通路在少突胶质前体细胞中的作用:重点关注 ROS 保护、线粒体生物发生和促进细胞分化。
Int J Mol Sci. 2020 Sep 29;21(19):7216. doi: 10.3390/ijms21197216.
9
Lipid and energy metabolism in Wilson disease.威尔逊病中的脂质与能量代谢
Liver Res. 2020 Mar;4(1):5-14. doi: 10.1016/j.livres.2020.02.002. Epub 2020 Feb 19.
10
Oxylipin Profiles in Plasma of Patients with Wilson's Disease.威尔逊病患者血浆中的氧化脂质谱。
Metabolites. 2020 May 29;10(6):222. doi: 10.3390/metabo10060222.